Pulmonary embolism (PE) is the third leading cause of cardiovascular mortality in the U.S., with intermediate-risk PE accounting for 35-55% of hospitalized cases and a mortality rate of 5-24%. Current treatment involves anticoagulation, but adverse outcomes have led to considering more aggressive therapies. The APEX trial and clinical conversation focus on evaluating a new mechanical thrombectomy device for improving patient outcomes.
William Brent Keeling, MDPanelist
At the end of this activity, participants should be able to:• Discuss the clinical significance of acute intermediate-risk PE and the role of mechanical vacuum-assisted thrombectomy in its management• Analyze the clinical efficacy of the AlphaVac F1885 System in patients with acute intermediate-risk PE• Evaluate the safety outcomes associated with percutaneous mechanical aspiration thrombectomy, focusing on the incidence of major adverse events (MAEs) within 48 hours post-procedure
Accreditation StatementThe Society for Cardiovascular Angiography and Interventions (SCAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit DesignationSCAI designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 0.25 MOC points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABIM MOC credit.
Successful CompletionWatch the content and complete the evaluation to obtain credit.Activity TimelineRecorded: 2/27/25Publish date: 4/21/25Expiration date: 4/21/28